Moderna lowered the top end of its 2025 revenue forecast by $200 million on Thursday, citing weaker-than-expected sales of ...

Europe's drugs regulator said on Friday it had launched a real-time review of CureVac's (5CV.DE), COVID-19 vaccine to speed ...

Following restricted vaccine approvals and changes to CDC immunization schedules, Merck, Pfizer, GSK and Sanofi are all ...

MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.

MRNA posts narrower-than-expected Q3 loss and lifts liquidity outlook for 2025, as cost cuts and revised spending plans boost investor sentiment ...

Moderna posted a smaller-than-expected quarterly loss and reduced its annual operating expenses outlook by $700 million on ...

First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. | First, the phase 3 trial of ...

Antimicrobial or antibiotic resistance (AMR) is one of the most urgent threats to global health, with wide-ranging ...

The conference hall of Dover Hotel in Ikeja, Lagos, buzzed with an unusual mix of energy and urgency on Thursday morning, ...

Pfizer (PFE) stock is in focus as the company exceeds Street forecasts with its Q3 2025 results thanks mainly to its COVID ...

When all is done, Vaxart could get more money in this new deal than it was set to get under its Health and Human Services ...

Moderna Inc became the second U.S company to release data from a large study of its experimental vaccine, saying it was 94.5% effective against COVID-19.